Current issue
About the Journal
Scientific Council
Editorial Board
Regulatory and archival policy
Code of publishing ethics
Publisher
Information about the processing of personal data in relation to cookies and newsletter subscription
Archive
For Authors
For Reviewers
Contact
Reviewers
Annals reviewers in 2022
Annals reviewers in 2021
Annals reviewers in 2020
Annals reviewers in 2019
Annals reviewers in 2018
Annals reviewers in 2017
Annals reviewers in 2016
Annals reviewers in 2015
Annals reviewers in 2014
Annals reviewers in 2013
Annals reviewers in 2012
Links
Sklep Wydawnictwa SUM
Biblioteka Główna SUM
Śląski Uniwersytet Medyczny w Katowicach
Privacy policy
Accessibility statement
12-month assessment of increase in total kidney volume in children and young adults with autosomal dominant polycystic kidney disease – a pilot study
Marcin Tkaczyk
1,6
| 1 | Klinika Pediatrii, Immunologii i Nefrologii, Instytut Centrum Zdrowia Matki Polki, Łódź |
| 2 | Zakład Diagnostyki Obrazowej, Instytut Centrum Zdrowia Matki Polki, Łodź |
| 3 | Instytut Informatyki, Politechnika Łódzka, Łódź |
| 4 | Klinika Kardiologii, Instytut Centrum Zdrowia Matki Polki, Łódź |
| 5 | Studenckie Koło Naukowe przy Klinice Pediatrii, Kardiologii Prewencyjnej i Immunologii Wieku Rozwojowego, Uniwersytet Medyczny w Łodzi |
| 6 | Zakład Dydaktyki Pediatrycznej, Uniwersytet Medyczny w Łodzi |
CORRESPONDING AUTHOR
Monika Pawlak-Bratkowska
Klinika Pediatrii, Immunologii i Nefrologii, Instytut Centrum Zdrowia Matki Polki, ul. Rzgowska 281/289, 93-338 Łódź
Klinika Pediatrii, Immunologii i Nefrologii, Instytut Centrum Zdrowia Matki Polki, ul. Rzgowska 281/289, 93-338 Łódź
Ann. Acad. Med. Siles. 2017;71:109–115
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Autosomal dominant polycystic kidney disease (ADPKD) is the most common type of monogenic kidney disease. It is the cause of ESRD in 5–10% of adult patients who undergo renal replacement therapy. Owing to the increasing use of ultrasonography, occurrence of the disease has been observed among children.
Material and methods:
The research group consisted of 19 patients with normal kidney function (12 girls and 7 boys aged 1.8–18.8 at the moment of examination) who suffered from ADPKD. 15 patients met the ultrasonographic criteria of the diagnosis. Although the remaining 4 patients did not meet the criteria, they had a strong family history of ADPKD and underwent USG which revealed at least 2 cysts. For each patient, the Total Kidney Volume (TKV), defined as the sum volume of both kidneys, was juxtaposed with BSA. The children underwent the examination approximately every 12 months.
Results:
The members of the research group manifested a statistically significant annual increase in TKV (in 2015, 296.71 ± 178.67 cm3 versus 350.38 ± 195.86 cm3 in 2016, p = 0.019), as well as TKV in relation to body surface (in 2015, 191.23 ± 86.29 cm3/m2 versus 221.15 ± 96.99 cm3/m2 in 2016, p = 0.037). There were no apparent differences in the rate of total TKV increase which would depend either on the patient's gender (girls 32.45 ± 51.88 cm3/m2/year versus boys 25.56 ± 71.00 cm3/m2/year, p = 0.81), or on the number of renal cysts revealed by USG (< 5 cysts 30.77 ± 61.6 cm3/m2/year versus ≥ 5 cysts 29.41 ± 58.22 cm3/m2/year, p = 0.96).
Conclusions:
In children and young adults with ADPKD, the increase in total kidney volume (in relation to BSA) can be observed after a 12-month observation.
Autosomal dominant polycystic kidney disease (ADPKD) is the most common type of monogenic kidney disease. It is the cause of ESRD in 5–10% of adult patients who undergo renal replacement therapy. Owing to the increasing use of ultrasonography, occurrence of the disease has been observed among children.
Material and methods:
The research group consisted of 19 patients with normal kidney function (12 girls and 7 boys aged 1.8–18.8 at the moment of examination) who suffered from ADPKD. 15 patients met the ultrasonographic criteria of the diagnosis. Although the remaining 4 patients did not meet the criteria, they had a strong family history of ADPKD and underwent USG which revealed at least 2 cysts. For each patient, the Total Kidney Volume (TKV), defined as the sum volume of both kidneys, was juxtaposed with BSA. The children underwent the examination approximately every 12 months.
Results:
The members of the research group manifested a statistically significant annual increase in TKV (in 2015, 296.71 ± 178.67 cm3 versus 350.38 ± 195.86 cm3 in 2016, p = 0.019), as well as TKV in relation to body surface (in 2015, 191.23 ± 86.29 cm3/m2 versus 221.15 ± 96.99 cm3/m2 in 2016, p = 0.037). There were no apparent differences in the rate of total TKV increase which would depend either on the patient's gender (girls 32.45 ± 51.88 cm3/m2/year versus boys 25.56 ± 71.00 cm3/m2/year, p = 0.81), or on the number of renal cysts revealed by USG (< 5 cysts 30.77 ± 61.6 cm3/m2/year versus ≥ 5 cysts 29.41 ± 58.22 cm3/m2/year, p = 0.96).
Conclusions:
In children and young adults with ADPKD, the increase in total kidney volume (in relation to BSA) can be observed after a 12-month observation.
REFERENCES (35)
1.
Grams M.E., Sang Y., Ballew S.H., Gansevoort R.T., Kimm H., Kovesdy C.P., Naimark D., Oien C., Smith D.H., Coresh J., Sarnak M.J., Stengel B., Tonelli M.A. Meta-analysis of the Association of Estimated GFR, Albuminuria, Age, Race, and Sex With Acute Kidney Injury. Am. J. Kidney Dis. 2015; 66(4): 591–601.
2.
Chapman A.B., Torres V.E., Perrone R.D., Steinman T.I., Bae K.T., Miller J.P., Miskulin D.C., Rahbari Oskoui F., Masoumi A., Hogan M.C., Winklhofer F.T., Braun W., Thompson P.A., Meyers C.M., Kelleher C., Schrier R.W. The HALT polycystic kidney disease trials: Design and implementattion. Clin. J. Am. Soc. Nephrol. 2010; 5: 102–109.
3.
Chapman A.B., Guay-Woodford L.M., Grantham J.J., Torres V.E., Bae K.T., Baumgarten D.A., Kenney P.J., King B.F. Jr, Glockner J.F., Wetzel L.H., Brummer M.E., O'Neill W.C., Robbin M.L., Bennett W.M., Klahr S., Hirschman G.H., Kimmel P.L., Thompson P.A., Miller J.P. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int. 2003; 64(3): 1035–1045.
4.
Fick G.M., Johnson A.M., Strain J.D., Kimberling W.J., Kumar S., Manco-Johnson M.L., Duley I.T., Gabow P.A. Characteristic of very early onset autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 1993; 3: 1863–1870.
5.
MacDermot K.D., Saggar-Malik A.K., Economides D.L., Jeffery S. Prenatal diagnosis of autosomal dominant polycystic kidney disease (PKD1) presenting in utero and prognosis for very early onset disease. J. Med. Genet. 1998; 35(1): 13–16.
6.
Al-Bhalal L., Akhtar M. Molecular basis of autosomal dominant polycystic kidney disease. Adv. Anat. Pathol. 2005; 12(3): 126–133.
7.
Pei Y., Hwang Y.H., Conklin J., Sundsbak J.L., Heyer C.M., Chan W., Wang K., He N., Rattansingh A., Atri M., Harris P.C., Haider M.A. Imaging-Based Diagnosis of Autosomal Dominant Polycistic Kidney Disease. J. Am. Soc. Nephrol. 2015; 26: 746–753.
8.
Pei Y., Obaji J., Dupuis A., Paterson A.D., Magistroni R., Dicks E., Parfrey P., Cramer B., Coto E., Torra R., San Millan J.L., Gibson R., Breuning M., Peters D., Ravine D. Unified Criteria for Ultrasonographic Diagnosis of ADPKD. J. Am. Soc. Nephrol. 2009; 20: 205–212.
9.
Ettinger A., Kahn P.C., Wise H.M. Jr. The importance of selective renal angiography in the diagnosis of polycystic disease. J. Urol. 1969; 102(2): 156–161.
10.
Chebib F.T., Torres V.E. Autosomal dominant polycystic kidney disease: Core curriculum 2016. Am. J. Kidney Dis. 2016; 67(5): 792–810.
11.
Helal I., Reed B., Schrier R.W. Emergent Early Markers of Renal Progression in Autosomal-Dominant Polycystic Kidney Diseade Patients: Implications for Prevention and Treatment. Am. J. Nephrol. 2012; 36: 162–167.
12.
Helal I., Reed B., McFann K., Yan X.D., Fick-Brosnahan G.M., Cadnapaphornchai M., Schrier R.W. Glomerular Hyperfiltration and Renal Progression i Children with Autosomal Dominant Polycystic Kidney Disease. Clin. J. Am. Soc. Nephrol. 2011; 6: 2439–2443.
13.
Fick-Brosnahan G.M., Tran Z.V., Johnson A.M, Strain J.D., Gabow P.A. Progression of autosomal-dominant polycystic kindey disease in children. Kidney Int. 2001; 39: 1654–1662.
14.
Chapman A.B., Devuyst O., Eckardt K.U., Gansevoort R.T., Harris T., Horie S., Kasiske B.L., Odland D., Pei Y., Perrone R.D., Pirson Y., Schrier R.W., Torra R., Torres V.E., Watnick T., Wheeler D.C. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes ((KDIGO) Controversies Conference. Kidney Int. 2015; 88(1): 17–27. doi: 10.1038/ki.2015.59.
15.
Helal I., McFann K., Reed B., Yan X.D., Schrier R.W., Fick-Brosnahan G.M. Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease. Nephrol. Dial. Transplant. 2013; 28: 380–385.
16.
Ravine D., Gibson R.N., Walker R.G., Sheffield L.J., Kincaid-Smith P., Danks D.M. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet. 1994; 343(8901): 824–827.
17.
Cadnapaphornchai M.A., McFann K., Strain J.D., Masoumi A., Schrier R.W. Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hipertension. Kidney Int. 2008; 74(9): s. 1192–1196.
18.
Shamshirsaz A., Bekheirnia R.M., Kamgar M., Johnson A.M., McFann K., Cadnapaphornchai M., Nobakhthaghighi N., Schrier R.W. Autosomaldo-minant polycystic kidney disease in infancy and childhood: Progression and outcome. Kidney Int. 2003; 68: 2218–2224.
19.
Schrier R.W., Brosnahan G., Cadnapaphornchai M.A., Chonchol M., Friend K., Gitomer B., Rossetti S. Predictors of Autosomal Dominant Polycystic Kidney Disease Progression. J. Am. Soc. Nephrol. 2014; 25: 2399–2418.
20.
Gabow P.A., Johson A.M., Kaehny W.D., Kimberling W.J., Lezotte D.C., Duley I.T., Jones R.H. Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int. 1992; 41: 1311–1319.
21.
Chapman A.B., Guay-Woodford. Renal volume in children with ADPKD: Size matters. Clin. Am. Soc. Nephrol. 2009; 4: 698–699.
22.
Alam A., Dahl N.K., Lipschutz J.H., Rossetti S., Smith P., Sapir D., Weinstein J., McFarlane P., Bichet D.G. Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease: A Biomarker of Disease Progression and Therapeutic Efficacy. Am. J. Kidney Dis. 2015; 66(4): 564–576.
23.
Corradi V., Gastaldon F., Virzì G.M., Caprara C., Martino F., Ronco C. Clinical and laboratory markers of autosomal dominant polycystic kidney disease (ADPKD) progression: an overview. Minerva Med. 2015; 106(1): 53–64.
24.
Higashihara E., Nutahara K., Okegawa T., Shishido T., Tanbo M., Kobayasi K., Nitadori T. Kidney volume and function in autosomal dominant polycystic kidney disease. Clin. Exp. Nephrol. 2014; 18(1): 157–165.
25.
Fick-Brosnahan G.M., Belz M.M., McFann K.K., Johnson A.M., Schrier R.W. Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study. Am. J. Kidney Dis. 2002; 39(6): 1127–1134.
26.
Grantham J.J., Torres V.E.,Chapman A.B., Guay-Woodford L.M., Bae K.T., King B.F. Jr, Wetzel L.H., Baumgarten D.A., Kenney P.J., Harris P.C., Klahr S., Bennett W.M., Hirschman G.N., Meyers C.M., Zhang X., Zhu F., Miller J.P. Volume progression in polycystic kidney disease. N. Engl. J. Med. 2006; 354: 2122–2130.
27.
Masoumi A., Elhassan E., Schrier R.W. Interpretation of renal volume in autosomal dominant polycystic kidney disease and relevant clinical implications. Iran J. Kidney Dis. 2011; 5(1): 1–8.
28.
Chen D., Ma Y., Wang X., Yu S., Li L., Dai B., Mao Z., Sun L., Xu C., Rong S., Tang M., Zhao H., Liu H., Serra A.L., Graf N., Liu S., Wüthrich R.P., Mei C. Clinical characteristics and disease predictors of a large Chinese cohort of patients with autosomal dominant polycystic kidney disease. PLoS One. 2014; 9(3): e92232.
29.
Fick G.M., Johnson A.M., Hammond W.S., Gabow P.A. Causes of death in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 1995; 5(12): 2048–2056.
30.
Schrier. Renal volume, renin-angiotensin-aldosterone system, hyper-tension, and ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J. AM. Soc. Nephrol. 2009; 20: 1888–1893.
31.
Gabow P.A., Chapman A.B., Johnson A.M., Tangel D.J., Duley I.T., Kaehny W.D., Manco-Johnson M., Schrier R.W. Renal structure and hypertension in autosomal dominant polycystic kidney disease. Kidney Int. 1990; 38: 1177–1180.
32.
Kelleher C.L., McFann K.K., Johnson A.M., Schrier R. Characteristics of hypertension in young adults with autosomal dominant polycystic kidney disease compared eth t. AJH. 2004; 17: 1029–1034.
33.
Schrier R., McFann K., Johnson A., Chapman A., Edelstein C., Brosnahan G., Ecder T., Tison L. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J. Am. Soc. Nephrol. 2002; 13(7): 1733–1739.
34.
Fick G.M., Duley I.T., Johnson A.M., Strain J.D., Manco-Johnson M.L., Gabow P.A. The spectrum of autosomal dominant polycystic kidney disease in children. J. Am. Soc. Nephrol. 1994; 4(9): 1654–1660.
35.
Bhutani H., Smith V., Rahbari-Oskoui F., Mittal A., Grantham J.J., Torres V.E., Mrug M., Bae K.T., Wu Z., Ge Y., Landslittel D., Gibbs P., O'Neill W.C., Chapman A.B. A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease. Kidney Int. 2015; 88(1): 146–151.
RELATED ARTICLE
The Medical University of Silesia in Katowice, as the Operator of the annales.sum.edu.pl website, processes personal data collected when visiting the website. The function of obtaining information about Users and their behavior is carried out by voluntarily entered information in forms, saving cookies in end devices, as well as by collecting web server logs, which are in the possession of the website Operator. Data, including cookies, are used to provide services in accordance with the Privacy policy.
You can consent to the processing of data for these purposes, refuse consent or access more detailed information.
You can consent to the processing of data for these purposes, refuse consent or access more detailed information.